You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 2, February 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (16)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Psoriasis
 •Dermatologic Procedures
 •Phototherapy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Narrowband (312-nm) UV-B Suppresses Interferon {gamma} and Interleukin (IL) 12 and Increases IL-4 Transcripts

Differential Regulation of Cytokines at the Single-Cell Level

Ian B. Walters, MD; Maki Ozawa, MD, PhD; Irma Cardinale, BS; Patricia Gilleaudeau, FNP; William L. Trepicchio, PhD; Judith Bliss, BS; James G. Krueger, MD, PhD

Arch Dermatol. 2003;139:155-161.

Objective  To determine whether 312-nm UV-B alters production of effector and regulatory cytokines by viable T cells that remain in psoriatic lesions during UV-B phototherapy.

Design  Prospective study.

Setting  General clinical research center of The Rockefeller University Hospital.

Patients  Ten adult patients with moderate to severe psoriasis vulgaris that was difficult to manage were sequentially enrolled in our protocols, and biopsies were taken at various time points from resolving lesions.

Intervention  Narrowband (312-nm) UV-B was given starting at 50% of a minimum erythema dose, then increased daily 10% to 15% if no apparent erythema was induced. Patients continued with treatment until maximal benefit was noted. In some experiments, T cells were irradiated ex vivo with standard TL-01 fluorescent bulbs (Philips Lighting Co, Somerset, NJ).

Main Outcome Measures  Intracellular cytokine staining was done using flow cytometry to quantify numbers of cytokine-producing cells from epidermal and peripheral T cells. The production of messenger RNA for interleukin (IL) 12, interferon (IFN) {gamma}, tumor necrosis factor {alpha}, IL-4, and IL-10 was measured by quantitative reverse transcription–polymerase chain reaction.

Results  Ultraviolet-B treatment eliminated production of IL-12 messenger RNA and decreased production of IFN-{gamma} messenger RNA by more than 60% in irradiated psoriasis lesions (P<.03 for both). Within 1 to 2 weeks of starting UV-B treatment, the frequency of viable T cells producing IFN-{gamma} decreased 40% to 65%. In contrast, mRNA for IL-4 increased by 82% (P = .05) during UV-B treatment, and the number of IL-4–producing cells increased by 228% after 1 week of treatment. In vitro experiments established that, on the single-cell level, survival and cytokine production by type 1 T cells were differentially regulated by UV-B.

Conclusions  Therapeutic UV-B suppresses the type 1 (proinflammatory) axis as defined by IL-12, IFN-{gamma}, and IL-8, and can selectively reduce proinflammatory cytokine production by individual T cells. Knowledge of the immunomodulatory effects of UV-B will help to integrate this modality in future therapeutics for psoriasis based on deliberate blockade of inflammatory molecular pathways in the type 1 T-cell pathway.


From the Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of Both Ultraviolet B Irradiation and Histamine Receptor Function on Allergic Responses to an Inhaled Antigen
McGlade et al.
J. Immunol. 2007;178:2794-2802.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.